STOCKWATCH: The strategic review – a prelude to value destruction
This article was originally published in Scrip
The news that a company is conducting a strategic review has grandiose implications of high-flying investment bankers, consultants and board members scouring the world and the management literature for examples of how successful companies have moved from strength to strength, and then how those lesions can be applied to the company in question.
You may also be interested in...
After the differing second-quarter financial performances of Roche, AstraZeneca and Pfizer’s oncology franchises, the reports by Merck & Co and BMS should have helped define the effects of the pandemic on oncology businesses.
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.